Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2023-07-09 Regulatory Filings
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
NTI Receives HREC Approval for Rett Syndrome Clinical Trial 6 pages 233.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 10 July 2023 from Neurotech International Limited. It announces the receipt of Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) scheme clearance to commence a Phase I/II clinical trial for a drug (NTI164) targeting Rett Syndrome. The document provides detailed information about the clinical trial design, investigators, endpoints, inclusion/exclusion criteria, and background on the disease and drug. There are no financial statements, earnings data, or regulatory certifications. The content is focused on a clinical trial approval and study details rather than financial or governance reporting. This type of announcement is a regulatory update about clinical trial progress and approvals, which does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. It is not a management or board change announcement. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-07-09 English
Notification of cessation of securities - NTI 5 pages 25.1KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Notification of cessation of +securities' and details the expiry of options (unexercised convertible securities) for Neurotech International Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. There is no financial performance data, management discussion, or regulatory certification. The document is an announcement about changes in the company's issued securities, specifically the cessation of certain options due to expiry. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as cessation of securities.
2023-06-29 English
Notification regarding unquoted securities - NTI 11 pages 48.3KB
Capital/Financing Update Classification · 95% confidence The document is a detailed notification regarding the issue of unquoted equity securities, specifically options, by Neurotech International Limited. It includes specifics such as the number of securities issued, exercise prices, expiry dates, and references to approvals at a General Meeting. The document is structured as a formal announcement to the ASX (Australian Securities Exchange) about the issuance of new classes of options, including details about the securities and their terms. It is not a financial report, earnings release, or management discussion, nor is it a proxy statement or AGM material. The content aligns with announcements related to capital structure changes, specifically the issuance of new securities. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the announcement itself, not a brief report publication notice or a certification. Hence, the classification is CAP with high confidence.
2023-06-27 English
NTI to Present at Rett Syndrome Foundation Meeting 2 pages 124.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 5 June 2023 from Neurotech International Limited. It announces an upcoming presentation at a scientific meeting (International Rett Syndrome Foundation Scientific Meeting) by a company associate professor. The content focuses on the presentation topic, clinical trial plans, and background information about the company and the disease. There are no financial statements, no detailed financial performance data, no regulatory filings, no voting results, no management or board changes, no earnings data, no capital or financing updates, and no legal proceedings. The document is a public announcement about a scientific presentation and clinical trial plans, not a report or transcript. It is not a report publication announcement because it does not mention a report release or availability. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2023-06-04 English
Results of Meeting 3 pages 112.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 1 June 2023 reporting the results of a General Meeting of Neurotech International Limited. It details the voting outcomes on various resolutions, including ratification of placement shares and issuance of options. The content focuses on the official results of shareholder votes at the meeting, with no financial statements or detailed financial analysis present. The document is approximately 4955 characters, which is concise and primarily serves to disclose voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-05-31 English
NTI Granted 2 Year Extension of Treatment for ASD Patients 2 pages 197.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 31 May 2023 from Neurotech International Limited. It discusses the granting of a two-year extension for a clinical trial treatment and the transition of patients to a compassionate use program. The content focuses on clinical trial updates, regulatory approvals (Human Research Ethics Committee clearance), and ongoing clinical development activities. There are no financial statements, earnings data, or detailed financial analysis present. The document is an announcement of a regulatory and clinical trial update rather than a financial report or detailed management discussion. It is not a report publication announcement since it contains substantive information about the trial extension and compassionate use program. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance updates that do not fit other specific categories.
2023-05-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.